Efficacy of levetiracetam as first-line therapy for neonatal clinical seizures and neurodevelopmental outcome at 12 months of age

Basit Öğe Kaydı
dc.contributor.authorKanmaz, Seda
dc.contributor.authorKoroglu, Ozge Altun
dc.contributor.authorTerek, Demet
dc.contributor.authorSerin, Hepsen Mine
dc.contributor.authorSimsek, Erdem
dc.contributor.authorCetin, Ipek Dokurel
dc.contributor.authorTekgul, Hasan L.
dc.date.accessioned2020-12-01T12:01:17Z
dc.date.available2020-12-01T12:01:17Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractAppropriate treatment of neonatal seizures with an effective therapy is important in reducing long-term neurologic disabilities. Sixty-seven neonates, who received intravenous (IV) levetiracetam (LEV) as first-line therapy for treating seizures between 2013 and 2017 were evaluated retrospectively to investigate the efficacy of LEV and its neurodevelopmental outcome at 12 months of age. of the 67 neonates (44 preterm and 23 term babies) evaluated for seizures, 55 (82%) had a defined etiology. EEG confirmation was obtained in 36 (57.1%) of the neonates with clinical seizures. on the 7th day of the treatment (mean seizure control time 7.4 +/- 15.1 days), LEV was effective as monotherapy in 43 (64%), whereas add-on therapy was required in 24 (36%) neonates. At the 1-year follow-up, 76% of infants achieved drug-free state, nine (18%) infants remained on LEV monotherapy and three (6%) needed add-on therapy. Neurodevelopmental outcome of the infants was assessed with Ankara Development Screening Inventory and results suggested favorable neurodevelopmental outcome in 69.7% of the infants with at the end of the 1-year follow-up with LEV monotherapy. in conclusion, this retrospective cross-sectional study demonstrated that IV LEV is an effective first-line therapy for treating neonatal clinical seizures and LEV monotherapy effect was sustained during the first year follow-up.en_US
dc.identifier.doi10.1007/s13760-020-01366-7en_US
dc.identifier.issn0300-9009
dc.identifier.issn2240-2993
dc.identifier.pmid32424740en_US
dc.identifier.scopus2-s2.0-85085351043en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s13760-020-01366-7
dc.identifier.urihttps://hdl.handle.net/11454/62374
dc.identifier.wosWOS:000533846100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofActa Neurologica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeonatal seizureen_US
dc.subjectLevetiracetamen_US
dc.subjectFirst-line therapyen_US
dc.subjectNeurodevelopmental outcomeen_US
dc.subjectPrematurityen_US
dc.titleEfficacy of levetiracetam as first-line therapy for neonatal clinical seizures and neurodevelopmental outcome at 12 months of ageen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu